Carisoprodol: A marginally effective skeletal muscle relaxant with serious abuse potential

Hospital Pharmacy

Volumn 38, Issue 4, 2003, Pages 337-345

  Boothby, Lisa Anne ^a,d   Doering, Paul L ^b   Hatton, Randy C ^b,c  

^a Drug Information   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d NONE   (United States)

Author keywords

Carisoprodol; Skeletal muscle relaxants; Soma; Substance abuse

Indexed keywords

BENZODIAZEPINE DERIVATIVE; BETA ENDORPHIN; BUTALBITAL; CAFFEINE; CARISOPRODOL; CHLORMEZANONE; CHLORZOXAZONE; CORTICOSTEROID; CYCLOBENZAPRINE; CYTOCHROME P450 2C19; DEXTROPROPOXYPHENE; DIAZEPAM; LORAZEPAM; MEPROBAMATE; METAXALONE; METHOCARBAMOL; MUSCLE RELAXANT AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE AGONIST; ORPHENADRINE; PARACETAMOL; PHENOBARBITAL; PRASTERONE; SECBUTABARBITAL; SEDATIVE AGENT;

CLINICAL TRIAL; DROWSINESS; DRUG ABUSE; DRUG DEPENDENCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; EUPHORIA; HUMAN; LAW; MYALGIA; NONHUMAN; REVIEW; SEDATION; WITHDRAWAL SYNDROME;

EID: 0037384289     PISSN: 00185787     EISSN: None     Source Type: Journal    
DOI: 10.1177/001857870303800406     Document Type: Review

References (71)

1. Carrington J, Getter L, Brown RS. Diabetic neuropathy masquerading as glossodynia. J Am Dent Assoc. 2001;132(11):1549-51.
2. Stohler CS. Chronic orofacial pain: Is the puzzle unraveling? J Dent Educ. 2001;65(12):1383-92.
3. Capewell S, McMurray J. "Chest pain-please admit": Is there an alternative? BMJ. 2000;320:951-2.
4. Pain Assessment and Management: An Organizational Approach. Oakbrook Park, IL: Joint Commission on Accreditation of Healthcare Organizations (JCAHO); 2000, 13-32.
5. Acute Pain Management Guideline Panel. Acute Pain Management: Operative of Medical Procedures and Trauma. Clinical Practice Guideline [AHCPR Pub. No. 92-0032]. Rockville, MD: Agency for Health Care Policy and Research, Public Health Service, US Department of Health and Human Services; February, 1992.
6. American Pain Society. Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain. 4th ed. http://www.ampainsoc.org. Accessed January 9, 2002.
7. Littrell RA, Hayes LR, Stillner V. Carisoprodol (Soma): A new and cautious perspective on an old agent. South Med J. 1993;86(7):753-68.
8. Carisoprodol. DrugDex Monograph. Micromedex Healthcare Series. Vol. 114 (expires 12/02).
9. Elenbaas JK. Centrally acting oral skeletal muscle relaxants. Am J Hosp Pharm. 1980;37(10):1313-23.
10. Waldman HJ. Centrally acting skeletal muscle relaxants and associated drugs. J Pain Sympt Manage. 1994;9(7):434-41.
11. Roberge RJ, Lin E, Krenzelok EP. Flumazenil reversal of carisoprodol (Soma) intoxication. J Emerg Med. 2000;18(1):61-4.
12. Elenbaas JK. Centrally acting oral skeletal muscle relaxants. Am J Hosp Pharm. 1980;37:1313-23.
13. Brocks DR. Anticholinergic drugs used in Parkinson's disease: An overlooked class of drugs from a pharmacokinetic perspective. J Pharm Pharma Sci. 1999;2(2):39-46.
14. Schifano F, Marra R, Magni G. Orphenadrine abuse [letter]. South Med J. 1988;81:546-7.
15. Dalen P, Alvan G, Wakelkamp M, et al. Formation of meprobamate from carisoprodol is catalyzed by CYP2C19. Pharmacogenetics. 1996;6:387-94.
16. Olsen H, Koppang E, Alvan G, et al. Carisoprodol elimination in humans. Ther Drug Monit. 1994;16:337-40.
17. Nordeng H, Zahlsen K, Spigset O. Transfer of carisoprodol to breast milk. Ther Drug Monit. 2001;23:298-300.
18. Backer RC, Zumwakt R, McFeeley P, et al. Carisoprodol concentrations from different anatomical sites: Three overdose cases. J Anal Toxicol. 1990;14:332-4.
19. Lebby TI, Dugger K, Lipscomb JW, et al. Skeletal muscle relaxant ingestion. Vet Hum Toxicol. 1990;32:133-5.
20. Adams HR, Kerzee T, Morehead CD. Carisoprodol-related death in a child. J Forensic Sci. 1975;20:200-2.
21. Roth BA, Vinson DR, Kim S. Carisoprodol-induced myoclonic encephalopathy. J Toxicol Clin Toxicol. 1998;36:609-12.
22. Rust GS, Hatch R, Gums JG. Carisoprodol as a drug of abuse. Arch Fam Med. 1993;2(4):429-32.
23. Littrell RA, Sage T, Miller W. Meprobamate dependence secondary to carisoprodol (Soma) use. Am J Drug Alcohol Abuse. 1993;19(1):133-4.
24. Luehr JG, Meyerle KA, Larson EW. Mail-order (veterinary) drug dependence. JAMA. 1990;263(5):657.
25. Olsen H, Koppang E, Alvan G, et al. Carisoprodol elimination in humans. Ther Drug Monit. 1994;16(4):337-40.
26. Roache JD, Griffiths RR. Lorazepam and meprobamate dose effects in humans: Behavioral effects and abuse liability. J Pharmacol Exp Ther. 1987;243(3):978-88.
27. Baratta RR. A double-blind comparative study of carisoprodol, propoxyphene, and placebo in the management of low back syndrome. Curr Ther Res. 1976;20(3):233-40.
28. Cullen AP. Carisoprodol (Soma) in acute back conditions: A double blind, randomized, placebo controlled study. Curr Ther Res Clin Exp. 1976;20:557-62.
29. Gallardo F, Molgo J, Miyazaki C, et al. Carisoprodol in the treatment of myofascial pain-dysfunction syndrome. J Oral Surg. 1975;33(9):655-8.
30. Miller AR. Comparative study of Parafon Forte tablets and Soma Compound in the treatment of painful skeletal muscle conditions. Curr Ther Res Clin Exp. 1976;19:444-50.
31. Hindle TH. Comparison of carisoprodol, butabarbital, and placebo in treatment of the low back syndrome. Calif Med. 1972;117:7-11.
32. Rollings HE, Glassman JM, Soyka JP. Management of acute musculoskeletal conditions - thoracolumbar strain or sprain: A double-blind evaluation comparing the efficacy and safety of carisoprodol with cyclobenzaprine hydrochloride. Curr Ther Res. 1983;34:917-28.
33. Vaeroy H, Abrahamsen A, Forre O, et al. Treatment of fibromyalgia (fibrositis syndrome): A parallel double-blind trial with carisoprodol, paracetamol and caffeine (Somadril comp) vs placebo. Clin Rheumatol. 1989;8(2):245-50.
34. Snell W, Corrigan RF, Zimerman RC. Comparative drug evaluation in treatment of skeletal muscle spasm. Clin Med. 1965;72:957-72.
35. Cooper CD. Comparative effects of diazepam, chlormezanone, and carisoprodol in musculoskeletal disorders. West J Med. 1963;4:34-9.
36. Waldman HJ. Centrally acting skeletal muscle relaxants and associated drugs. J Pain Symptom Manage. 1994;9:434-41.
37. National Institute on Drug Abuse. Statistical Series. Data from the Drug Abuse Warning Network (DAWN) 2001. http://www.samhsa.gov/oas/ DAWN/DetEDAnnual/2001/Text/DetEDtext.pdf. Rockville, MD. Acessed November 20, 2002.
38. Morse RM, Chua L. Carisoprodol dependence: A case report. Am J Drug Alcohol Abuse. 1978;5(4):527-30.
39. Elder NC. Abuse of skeletal muscle relaxants. Am Fam Physician. 1991;44(4):1223-6.
40. Reeves RR, Pinkofsky HB, Carter OS. Carisoprodol: A drug of continuing abuse. J Am Osteopath Assoc. 1997;97(12):723-4.
41. Reeves RR, Carter OS. Use of carisoprodol by substance abusers to modify the effects of illicit drugs. South Med J. 1999;92(4):441.
42. Reeves RR, Carter O, Pinkofsky HB, et al. Carisoprodol (Soma): Abuse potential and physician unawareness. J Addict Dis. 1999;18(2):51-6.
43. Reeves RR, Liberto V. Abuse of combinations of carisoprodol and tramadol. South Med J. 2001;94(5):512-4.
44. Bramness JG, Skurtveit S, Grung M, et al. Centrally acting muscle relaxants and traffic hazards. Tidsskr Nor Laegeforen. 2000;120(17):1966-9.
45. Logan BK, Case GA, Gordon AM. Carisoprodol, meprobamate, and driving impairment. J Forensic Sci. 2000;45(3):619-23.
46. Sikdar S, Basu D, Malhotra AK, et al. Carisoprodol abuse: A report from India. Acta Psychiatr Scand. 1993;88(4):302-3.
47. Wyller TB, Korsmo G, Gadeholt G. Dependence on carisoprodol (Somadril)? A prospective withdrawal study among prisoners. Tidsskr Nor Laegeforen. 1991;111(2):193-5.
48. Dougherty RJ. Carisoprodol should be a controlled substance. Arch Fam Med. 1995;4:582.
49. Ukens C. Carisoprodol abuse on rise, warns Mississippi Board. Drug Topics. 1992;19.
50. United States of America Department of Health and Human Services, Public Health Service Food and Drug Administration, Center for Drug Evaluation and Research. Drug Abuse Advisory Committee Meeting. February 11, 1997. http://www.fda.gov/ohrms/dockets/ac/97 /transcpt/3316t1.pdf. Accessed March 25, 2002.
51. Regulatory Update. Carisoprodol Addiction Studies Requested. ASAM News. 1997;12(4):1-2. http://www.asam.org/news/news10.htm. Accessed March 25, 2002.
52. National Institute on Drug Abuse Statistical Series. Data from the Drug Abuse Warning Network (DAWN), 2000. Rockville, MD: US Department of Health and Human Services. www.samsha.gov/statistics/statistics.htm 1. Accessed March 25, 2002.
53. Epidemiologic Trends in Drug Abuse. Volume 1: Highlights and Executive Summary. June 2001. CEWG: Community Epidemiology Work Group. National Institute of Drug Abuse. National Institute of Health. http://165. 112.78.61/CEWG/volumes/EXSUMJune 01.pdf. Accessed March 25, 2002.
54. National Institute on Drug Abuse Statistical Series. Data from the Drug Abuse Warning Network (DAWN), 2000. Rockville, MD: US Department of Health and Human Services. http://www.samhsa.gov/oas/DAWN/Final2k1EDtrends/text/EDtrend2001v6.pdf. Accessed November 20, 2002.
55. National Institute on Drug Abuse Statistical Series. Data from the Drug Abuse Warning Network (DAWN), 2000. Rockville, MD: US Department of Health and Human Services. http:// www.samhsa.gov/oas/dawn/Final2k1ED trends/PublishedTables/PubTablesCh12.xls. Accessed November 20, 2002.
56. The top 200 prescriptions for 2000 by number of US prescriptions dispensed. http://www.rxlist.com/top200.htm. Accessed October 24, 2001.
57. Abood R, Brushwood D. Pharmacy Practice and the Law. MD: Aspen Publications; 1997.
58. Applebe GE, Wingfield J. Pharmacy Law and Ethics. London: The Pharmaceutical Press; 1997.
59. Florida Pharmacy Association House of Delegates Resolution Manual 2000. Carisoprodol and Butorphanol Controls. http://www.pharmview.com/fpa/hod/Poli cystatements.htm. Accessed March 25, 2002.
60. Minutes from the Florida Board of Pharmacy Meeting. http://www9.myflorida.com/mqa/pharmacy/min_10-08-01.pdf. Accessed March 25, 2002.
61. http://www.soma-compound-carisoprodol-muscle-relaxants-drug-medication.com. General information about Soma; explanation of how one can order Soma without a prescription. Accessed November 20, 2002.
62. https://www.esecureprofessional.com/drug/soma-compound_com/html/order.htm. Patient enters personal information including height, weight, drug allergies, symptoms, and billing information. Accessed November 20, 2002.
63. http://www.247-pharmacy. com/Mio_Relax.htm. General information about Soma; advertises that one can order Soma without a prescription and without consultation fees. Accessed November 20, 2002.
64. http://www.accessmednet.com/prescription-drug-information/soma- carisoprodol.htm. General information about Soma; advertises that one can order Soma without a prescription and without consultation fees. Accessed November 20, 2002.
65. http://www.behavenet.com/capsules/treatments/drugs/carisoprodol.htm. Overseas prescriptions when prescribing doctor is listed for contact information. Accessed November 20, 2002.
66. http://www.overseasdrugstore.com/. Overseas prescriptions when prescribing doctor is listed for contact information. Accessed November 20, 2002.
67. AMA, JCAHO, and NCQA to Focus on Measuring the Effectiveness of Appropriate Pain Management. http://www.jcaho.org/news/nb350.html. Accessed March 25, 2002.
68. Veith JL, Anderson J, Slade SA, et al. Plasma beta-endorphin, pain thresholds and anxiety levels across the human menstrual cycle. Physiol Behav. 1984;32(1):31-4.
69. Sherman RA, Gall N, Gormly J. Treatment of phantom limb pain with muscular relaxation training to disrupt the pain-anxiety tension cycle. Pain. 1979;6(1):47-55.
70. Lipitz JS, Malanga GA. Oral medications in the treatment of acute low back pain. Occup Med. 1998;13:151-66.
71. Wesson DR, Smith DE, Ling W, et al. Sedative-hypnotics and tricyclics: Phenobarbital for carisoprodol withdrawal. In Lowinson JH, Ruiz P, Millman RB, et al, eds. Substance Abuse: A Comprehensive Textbook. 3rd ed. Baltimore: William and Wilkins; 1997, 223-8.